UPLOAD Filing
SOLIGENIX, INC.
Date: Sept. 2, 2025 · CIK: 0000812796 · Accession: 0000000000-25-009452
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Soligenix, Inc. Draft Registration Statement on Form S-1 Submitted August 27, 2025 CIK No. 0000812796 Dear Christopher Schaber:
September 2, 2025
Christopher Schaber Chief Executive Officer Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Driscoll R. Ugarte, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> September 2, 2025 Christopher Schaber Chief Executive Officer Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 Re: Soligenix, Inc. Draft Registration Statement on Form S-1 Submitted August 27, 2025 CIK No. 0000812796 Dear Christopher Schaber: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Driscoll R. Ugarte, Esq. </TEXT> </DOCUMENT>